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           Introduction 
                                        INTRODUCTION
Hyperlipidemia:
                         Hyperlipidemia is a condition when abnormally high levels of lipids
i.e.  the  fatty  substances  are  found  in  the  blood.  This  condition  is  also  called
hypercholesterolemia or  hyperlipoproteinemia.  Human body is  complex  machinery
and for maintaining the homeostasis various organ and organ system contributes. Any
undesirable change (if occurs) will disturb the balance resulting in diseased state. The
same way, the change in the level of lipids (They are naturally occurring molecules,
which are main component of cell membrane. They acts as blood transporter and their
main function is energy storage) will lead to many complications. Virchow in 19th
century who identified cholesterol  crystals  in  atherosclerotic lesion and stated that
endothelial cell injury initiates atherogenesis1.
                        In a modification of this hypothesis, it was proposed that the
endothelium  normally  influences  the  behavior  of  arterial  smooth  muscle  cells  by
providing a barrier to the passage of plasma proteins, and that the major effect of
hemodynamic  or  other  factors  that  injure  the  endothelium  is  to  reduce  the
effectiveness of the barrier2.  But now it is  clear that higher lipids level,  especially
cholesterol  and triglycerides  leads to  hyperlipidemia which ultimate speeds up the
process  of  atherosclerosis  and  disease  associated  with  it3. Arteries  are  normally
smooth and unobstructed on the inside, but in case of increased lipid level, a sticky
substance called plaque is formed inside the walls of arteries. This leads to reduced
blood flow, leading to stiffening and narrowing of the arteries4.
                   Decisions about treatment of elevated lipids currently focus on the LDL
cholesterol level as well as the cardiovascular risk status of the individual. In 1991, the
National  Cholesterol  Education Program (NCEP) of  the National  Heart  Blood and
Lung Institute (NHLBI) proposed criteria for “acceptable,” “borderline,” and “high”
levels of LDL and TC in children and adolescents5. These criteria have been adopted
as the basis for policy statements and treatment guidelines  by many organizations,
including  the  American  Academy  of  Pediatrics  (AAP),6 the  American  Heart
Association (AHA),7and the American Medical Association’s (AMA) Guidelines for
Adolescent Preventive Services.8
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                    In adults, LDL is strongly associated with a higher risk, and HDL is
associated with a lower risk of coronary heart disease (CHD). Lowering lipids through
dietary  or  pharmacological  therapy  has  been  shown  to  decrease  the  incidence  of
atherosclerotic events. Since lipid levels have been observed to track into adulthood,
adolescents with hyperlipidemia are also at greater CHD risk. The extent of abnormal
lipids  and  other  cardiovascular  risk  factors  during  childhood  and  adolescence  is
related to the severity of atherosclerosis seen in autopsies of young adults9.
                      Hypercholesterolemia is a metabolic condition that determines the onset
of  chronic  degenerative  diseases  such  as  atherosclerosis.  The  formation  of  initial
lesions appears to originate, more often, from the focal increase in lipoprotein content
within  regions  of  the  intima,  due  not  only  to  changes  in  the  permeability  of  the
overlying endothelium, but mainly because they bind to constituents of the cellular
matrix, increasing the residence time of lipid-rich particles within the arterial wall. In
the extracellular space of the intima, lipoproteins may undergo changes and evidence
points to a pathogenic role for such modifications. Hypercholesterolemia, therefore, is
an  important  risk  factor  for  cardiovascular  diseases  and  reduction  of  plasma
cholesterol  and  endothelial  protection  become  important  steps  for  the  control  of
atherosclerotic disease and its complications such as acute myocardial infarction and
systemic hypertension.10
                     Due to this, there is a constant search for new drugs to prevent or reduce
damage  caused  by  genetic  problems  or  excess  fat  diets  that  lead  to
hypercholesterolemia. To that end, attempts have been made to cause an increase in
plasma  cholesterol  using  laboratory  animals  to  better  understand  the  relationship
between changes in lipid metabolism and atherogenesis and to test possible treatments
for their reduction.11Triton WR1339 is a non-anionic detergent of polymeric structure
that has been successfully used in several studies to induce hypercholesterolemia.12
             High fat diet is regarded as an important factor to induce hyperlipidemia,
atherosclerosis. Hyperlipidemia always associated with diabetes mellitus.13 About 17
million  people  around  the  world  die  because  of  cardiovascular  diseases  every
year.14 30% global deaths are due to cardio vascular disease of global deaths in which
80%  deaths  occur  in  low  and  middle  income  countries.15 The  major  treatment
available  for  the  hyperlipidemia  includes  statins, fibrates, bile
acid sequestrents.16,17,18 The major side effects of anti hyperlipidemic agents  include
muscle  toxicity,  psychiatric  adverse  reactions  include  depression,  memory
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loss, confusion aggressive reactions.19,20These affect the lifestyle again. Hence it is the
time to approach the hyperlipidemia ethno pharmacologically.
                     Searching the safe and potent remedies from the herbal origin for the
treatment  of hyperlipidemia  and  related  cardiovascular disorders  has  become  most
fascinating and desired area of research for the pharmacologists.  Literature review
showed that  some of  the medicinal  plants have been scientifically investigated and
reported against various disorders. Canthium dicoccumis extensively used in ayurveda
for  variety  of  condition.  However  its  antihyperlipidemic activity
has not been investigated scientifically so far.  Keeping in view of pathophysiological
complications  of  hyperlipidemia  and  therapeutic  efficacy of  herbal  medicines,  the
plant Canthium dicoccum has been evaluated for antihyperlipidemic activity.
                  Cholesterol, triglycerides, and phospholipids are the major lipids in the
body,  and  they  are  transported  as  complexes  of  lipid  and  proteins  known  as
lipoproteins.  Plasma  lipoproteins  are  spherical  particles  with  surfaces  that  consist
largely of phospholipids, free cholesterol, and protein and cores that consist mostly of
triglyceride and cholesterol ester. 
The three major classes of lipoproteins found in serum are 
1. Low-density lipoproteins (LDLs), 
2. High-density lipoproteins (HDLs), and 
3. Very low-density lipoproteins (VLDLs). 
                  Intermediate density lipoprotein resides between VLDL and LDL and is
included in the LDL measurement in routine clinical measurement. Abnormalities of
plasma lipoproteins can result in a predisposition to coronary,  cerebrovascular,  and
peripheral vascular arterial disease. Accumulating evidence over the last decades had
linked elevated total and LDL and reduced HDL to the development of coronary heart
disease  (CHD).  The  National  Cholesterol  Education  Program  (NCEP)  Adult
Treatment Panel III (ATP III) published its third report summarizing these data and
giving recommendations for the management of hypercholesterolemia in adults. This
report modifies earlier recommendations and provides a new way of risk-stratifying
patients based on multiple risk factors and the presence of diabetes and the metabolic
syndrome.  The  American  Heart  Association  (AHA)  also  provides  guidelines  for
primary and secondary prevention of CHD.
TYPES OF HYPERLIPIDEMIA: 
Hyperlipidemia can be broadly divided into: 
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Primary  hyperlipidemia
Secondary hyperlipidemia
Primary Hyperlipidemia :  Which is  due to Single gene defect:  It  is  familial  and
called  as  monogenic  or  genetic.  Polygenic  gene  defect:  Multiple  genetic  defect,
dietary and physical activity are caused due to it.LDL- low density lipoprotein, IDL-
Intermediate density Lipoprotein, VLDL-Very low density lipoprotein21(table 1.1)
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Table 1 : Types, occurrence and cause of different types of Primary  hyperlipidemia
Secondary hyperlipidemia:  It  is  associated  with  diabetes,  myxoedema,  nephritic
syndrome,  chronic  alcoholism,  with  use  of  drugs  like  corticosteroids,  oral
contraceptives, Beta blockers22 (Table 1.2)
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Table .2 : types, occurrence and cause of different types of secondaryhyperlipidemia
CAUSES OF HYERLIPIDEMIA: 
                    The main cause of hyperlipidemia includes changes in lifestyle habits in
which risk factor is mainly poor diet i.e with a fat intake greater than 40 percent of
total  calories,  saturated  fat  intake  greater  than  10  percent  of  total  calories;  and
cholesterol intake greater than 300 milligrams per day or treatable medical conditions .
Lifestyle  contributors  include  obesity,  not  exercising,  and  smoking.  Other  factors
include diabetes, kidney disease, pregnancy, and an underactive thyroid gland. Other
factors  that  cause  hyperlipidemia  without  any prevalence  information  includes  the
following23. 
Berardinelli-Seip congenital lipodystrophy – hyperlipidemia:
A rare genetic disorder having heptomegaly,  loss genetic disorder characterized by
diabetes mellitus, loss of body fat, hepatomegaly, enlarged genitals, increased skeletal
growth and other abnormalities24
Berardinelli-Seip congenital lipodystrophy, type 1 – hyperlipidemia: 
A rare  genetic  disorder  caused by a  defect  on the AGPAT2 gene on chromosome
9q34.325 characterized by early-onset diabetes mellitus, loss of body fat, serious insulin
resistance, high blood triglycerides and fatty liver 
Berardinelli-Seip congenital lipodystrophy, type 2 – hyperlipidemia: 
A rare genetic disorder caused by a defect on the BSCL2 gene on chromosome 11q13
by early-onset diabetes mellitus, loss of body fat, serious insulin resistance, high blood
triglycerides and fatty liver 26. 
Cholestasis :
It is a condition the bile flow from the liver to the duodenum is blocked. It is of two
types first one is caused by mechanical blockage in the duct system which occur from
a  gallstone  or  malignancy  and  other  type  is  metabolic  Cholestasis,  in  which
disturbances in bile formation occur because of genetic defects or acquired as a side
effect of many medications 27
Chromosome 15q, deletion: 
A rare chromosomal disorder which occurs because of deletion of genetic material
from the long arm of chromosome 28,29
Neuropathy, hereditary motor and sensory, Okinawa type: 
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A dominantly  inherited,  slow-progressing  motor  and  sensory  nerve  disease  which
primarily involves the proximal muscles (i.e. the muscles closest to the trunk of the
body)30
Chronic renal failure 
Metabolic syndrome 
Nephrotic syndrome – hyperlipidemia
Secondary Causes of Hyperlipidemia:
                       Early recognition of secondary dyslipidemia allows more aggressive
intervention and potential  amelioration of  CHD risk.  As in adults,  dyslipidemia  is
common in adolescents with diabetes, typically with elevated LDL and TG, and low
HDL.  In  children  and adolescents  with type  1 diabetes,  good glucose  control  and
physical activity are associated with lower TC.31 The prevalence of type 2 diabetes in
adolescents  is  increasing and is  associated with obesity,  low physical  activity,  and
high dietary fat intakes.32 There are several secondary causes of abnormal lipids that
may occur in adolescence.  Children small for gestational  age as infants have been
shown to have higher levels of cholesterol, especially those who exhibit poor catch-up
growth.33 The starved state that occurs in anorexia nervosa and the use of anabolic
steroids  are  both  associated  with  abnormal  lipids.  Certain  medications  for  acne,
seizure disorders, immunosuppression, and contraception can adversely affect lipids as
can a high carbohydrate diet or a ketogenic diet sometimes prescribed for refractory
epilepsy.  Adolescents with a history of a transplant also tend to have an abnormal
lipoprotein panel despite a TC in the normal range.
SYMPTOMS:
                     Generally hyperlipidemia does not have any noticeable symptoms but
they are usually discovered during routine examination or until it reaches the danger
stage of a stroke or heart attack. The deposits of cholesterol (known as xanthomas)
may form under the skin (especially around the eyes or along the Achilles tendon) in
individuals with familial forms of the disorder or in those with very high levels of
cholesterol in the blood. Individuals with hypertriglyceridemia may develop numerous
pimple-like lesions across their body and has body mass index greater than 30 kg/m2,
or waist size greater than 40 inches in men (35 inches in women)34. Extremely high
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levels of triglycerides may also result in pancreatitis, a severe inflammation of the
pancreas that may be life-threatening.
DIAGNOSIS OF HYPERLIPIDEMIA: 
As hyperlipidemia doesn't have any visible symptoms in early stages so we should get
a blood test for the sake of prevention at regular intervals. The National Cholesterol
Education  Program recommends  that  people  get  this  test  every 5  years  after  age
20.The  more  risk  factors  for  heart  disease  you  have,  the  more  aggressively  your
physician  will  treat  hyperlipidemia.  Most  blood  tests  measure  levels  of  LDL
(sometimes called  "bad")  cholesterol,  HDL (sometimes called  "good")  cholesterol,
total  cholesterol  (LDL plus  HDL),  and  triglycerides.  To  have  a  low risk  of  heart
disease, your desirable lipid levels are35
• LDL less than 130 mg/dL or < 70 if you have established diagnosis of diabetes 
• HDL greater than 40 mg/dL (men) or 50 mg/dL (women); 
• Total cholesterol less than 200 mg/dL; and 
• Triglycerides less than 200 mg/dL or 150 if you have established heart disease or
diabetes.
Lipid profile:
Total cholesterol and LDL cholesterol increase throughout life in men and women,
representing  an  atherogenic  pattern  characteristic  of  Western  society  diets  The
Helsinki  Heart  Study  shows  that  hypertriglyceridemia  and  low  HDL  levels  are
associated  with  obesity(body  mass  index  [BMI]  >26  kg/m2),  smoking,  sedentary
lifestyle,  blood  pressure  of  140/90  mm  Hg  or  greater,  and  a  blood  glucose
concentration above 4.4 mmol/L and that  the benefit  of  gemfibrozil(risk reduction
68%,  p <.03) was confined largely to overweight subjects. Hypertriglyceridemia in
certain instances e.g., diabetes mellitus, nephrotic syndrome, and chronic renal disease
and perhapsin women is associated with increased cardiovascular risk. This is thought
to  be  a  consequence  of  the  presence  of  atherogenic  lipoproteins  and  of
hypertriglyceridemia  being  a  marker  for  them,  since  triglycerides  usually  are  not
independently predictive for CHD.
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MECHANISM INVOLVED IN LIPID TRANSPORT:
Lipids  are  insoluble  in  water.  Hence,  they  are  transported  around  the  body  as
lipoproteins. Lipids originate from two sources: endogenous lipids, synthesized in the
liver, and exogenous lipids, ingested and processed in the intestine. Approximately 7%
of body’s  cholesterol  circulates  in  plasma in  the  form of  low density lipoproteins
(LDL). The level of plasma cholesterol is influenced by its synthesis and catabolism in
CLEARANCE OF LDL: 
Binding of LDL to cell surface receptor that  are clustered in specialized region of
plasma membrane, called as Coated pits. Binding causes coated pits to internalize by
invagination to form coated vesicles which fuse with lysosomes. Here LDL dissociates
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Fig: 1.1 The LDL receptor pathway and regulation of cholesterol metabolism
from  receptor  and  receptor  gets  recycled  to  the  surface.  Within  lysosomes  LDL
molecule is enzymatically degraded.
Indications for Treatment
National Cholesterol Education Program (NCEP) guidelines apply to adolescents with
either a positive family history of CHD or parental hyperlipidemia. Recommendations
for intervention vary depending upon the degree of elevation of the adolescent’s levels
of LDL or TC. The AAP’s 1998 guidelines are consistent with NCEP, but use only the
LDL level to make treatment decisions.
 Acceptable LDL or TC:  preventive dietary guidelines  and risk
factorreduction counseling.
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Fig:1.2 Transport of lipid in the body
 Borderline  LDL  or  TC:  AHA  Step  1  diet  plus  risk  factor
reduction counseling.
 High LDL:  Intensive nutrition assessment  if  LDL still  elevated
after three months.
AAP  recommendations  for  adolescents  with  “high”  LDL  also  include  ruling  out
secondary  causes  of  elevated  lipids  and  conducting  lipid  screening  on  all  family
members.
The NCEP ATP III Guidelines for Adults consider triglycerides as an independent risk
factor for CHD and target weight reduction and increased physical activity for those
with borderline TG levels (150-199 mg/dl). Specific recommendations have not been
made for adolescents with hypertriglyceridemia,  except for those with diabetes and
elevated TG.37
Treatment Goals
Ultimate NCEP goals for adolescents include reducing lipids to “acceptable” levels:
LDL cholesterol levels to <110 mg/dl and TC to <170 mg/dl. More realistic initial
goals are <130 for LDL and <200for TC, especially for those with initially high levels.
GENERAL APPROACH
Establishing targeted changes and outcomes with consistent  reinforcement  of goals
and measures at follow-up visits to attain goals are important to reduce barriers for
optimizing  TLC  and  pharmacologic  therapy.  TLC  should  be  implemented  in  all
patients prior to considering drug therapy. The components of TLC include reduced
intakes of saturated fats and cholesterol, dietary options to reduce LDL such as plant
stanols and sterols and increased soluble fiber intake, weight reduction, and increased
physical activity.  In  general,  physical activity of moderate intensity 30 minutes per
day for most days of the week should be encouraged. Patients with known CAD or at
high risk should be evaluated before undertaking vigorous exercise. Weight and body
mass index (BMI) should be measured at each visit, and lifestyle patterns to induce a
weight loss of 10% should be discussed in persons who are overweight. All patients
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also should be counseled to stop smoking and to meet the Joint National Committee 7
(JNC7) guidelines for control of hypertension.
Dietary Recommendations
Dietary intervention is the primary treatment strategy, but drug therapy may often be
added later to augment treatment. The main component of a “heart-healthy” diet is a
food pattern that is low in saturated fat and dietary cholesterol and provides adequate
energy to support growth and maintain an appropriate weight. The AHA expanded
these guidelines in 2000 to address omega-3 and  trans  fatty acids. Recently revised
NCEP adult treatment guidelines relaxed the restriction on monounsaturated and total
fat, and added dietary fiber guidelines.38Past interventions with youth have confirmed
the safety and efficacy of a low fat diet. As long as energy intake is sufficient, and
nutrient-dense foods are selected, a low fat, low cholesterol diet supports growth and
development. Specific dietary recommendations include:
 Decreased intakes of saturated fat: Reducing saturated fat is considered
to have the most
impact in lowering LDL. Sources include stick margarine, partially hydrogenated oils
and fats, hydrogenated peanut butters, commercial bakery products, commercial fried
food (e.g., French fries) and high fat animal products.
 Decreased intakes of  trans-fatty acids:  Trans-fatty acids are thought to
increase LDL levels nearly as much as saturated fat and appear to lower HDL.
 Decreased  intakes  of  dietary  cholesterol:  Although  individual
responsiveness to dietary
cholesterol varies, it is still considered important in LDL reduction. Diabetic patients
may be
more sensitive to dietary cholesterol intake,4 which is only found in animal products.
 Encourage a low to moderate total  fat intake:  Currently the specific
type  of fat  consumed is  emphasized over  the total  fat  intake which was once
considered to be the most important factor in lowering cholesterol. The AAP and
AHA  have  placed  upper  and  lower  limits  on  fat  intake  to  prevent  nutrient
deficiencies possible with very low fat diets and to avoid possible adverse effects
of high carbohydrate diets upon HDL and TG.39
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 Balance  the  fatty  acid  composition  of  diet:  Polyunsaturated  and
monounsaturated fatty acids can lower LDL and are suggested as substitutes for
saturated fats.
 Encourage  omega-3-fatty  acid  consumption:  Because  of  their
association with lower TG and other cardio protective effects, the AHA
recommends at least 1 fatty fish meal or other source of omega 3-fatty
acids per week.
 Increase  dietary  fiber  intake:  Soluble  fiber  can  contribute  to
LDL  reduction  and  is  now  a  formal  part  of  hyperlipidemia  dietary
recommendations.  Fruits,  vegetables,  cereals,  oats,  whole  grains,  and
legumes are good sources of soluble fiber.
 Encourage antioxidant food sources: Carotenoids and vitamins
C  and  E  have  been  associated  with  lower  CHD  risk.  Recommend
antioxidant-rich foods such as whole grains, citrus fruits, melons, berries
and dark orange/yellow or leafy green vegetables rather than supplements.
 Reduce  serum  homo  cysteine  levels:  Higher  blood  levels  of
homocysteine are associated with greater CHD risk. Adequate intakes of
folate and vitamins B6 and B12 as well as total fat restriction may keep
homo cysteine levels low.40 Food sources of these nutrients include fruits,
dark green and leafy vegetables, fortified cereals, whole grains, lean meats
and poultry.
 Plant  sterols  are  not  recommended:  Plant-sterol-containing
foods are associated with lower LDL, but may decrease the absorption of
fat-soluble  vitamins.  The  AHA  recommends  these  foods,  such  as
“cholesterol-lowering”  margarine-type  spreads  and  salad  dressings,
mainly  for  adults,  and  should  only  be  used  by  adolescents  who  are
hyperlipidemic and monitored closely for growth.
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Other Risk Factor Recommendations:
 Maintain  a  healthy  body  weight:  Recent
recommendations  stress  weight  management  to  optimize
LDL, HDL and TG levels. (See the discussion later in this
chapter  on special  sub groups  requiring modifications  to
treatment plan.)
 Increase physical activity
 Quit smoking (if applicable)
Over the past few years guidelines for the use of lipid-lowering therapy have become
more aggressive following the results of major trials showing mortality benefit for the
use of statins. Most guidelines recommend statin treatment for a patient with CAD
with a 10-year risk that is greater than 20% (high risk) once a trial of dietary therapy
has been unsuccessful. However, treatment can be cost effective with a 10-year risk of
10% 41
GOAL OF THERAPY: 
The goals  of  therapy are the reduction of LDL cholesterol  levels and the level  of
initiation of therapeutic lifestyle change (TLC) and proper drug therapy are for adults
and  children.  While  these  goals  are  surrogate  end  points,  the  primary  reason  to
institute TLC and drug therapy is to reduce the risk first or recurrent events such as
MI, angina, heart failure, ischemic stroke, or other forms of peripheral arterial disease
such as carotid stenosis or abdominal aortic aneurysm42. 
Treatment therapy involves two approaches: 
 Non-pharmacological therapy 
 Pharmacological therapy 
NON-PHARMACOLOGICAL THERAPY: 
                  The objectives of dietary therapy are to decrease the intake of total fat,
saturated fatty acids (i.e., saturated fat), and cholesterol progressively and to achieve a
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desirable body weight. The rationale for using a nutritionally balanced low-fat, low
cholesterol diet for the treatment of hypercholesterolemia is based on these principles:
(1)  It  represents  a  reasonable  extension  of  the  diet  recommended  for  the  general
public, (2) it progressively decreases the major cholesterol-raising constituent of the
diet, (3) it precludes large intakes of polyunsaturated fats, and (4) it facilitates weight
reduction by removing foods of high caloric density. The isomeric form of fatty acids
is also important. Fatty acids with the cis configuration are the preferred substrate for
the ACAT reaction and significantly increase hepatic LDL receptor clearance while
reducing LDL cholesterol production rate. The trans isomeric form cannot be used by
ACAT and is biologically inactive with no effect on LDL concentration.43
The objectives of dietary therapy are to decrease the intake of total fat, saturated fatty
acids 
 (i.e., saturated fat), and cholesterol progressively and to achieve a desirable body
weight 
  Reducing your saturated fat intake to 7 percent of your daily calories; 
  Reducing your total fat intake to 25 to 35 percent of your daily calories; 
  Limiting your dietary cholesterol to less than 200 mg per day; 
  Eating 20 to 30 g a day of soluble fiber, which is found in oats, peas, beans,
andcertain fruits; 
PHARMACOLOGIC THERAPY
                 There are now numerous randomized, double-blinded clinical trials demonstrating
that  reduction  of  LDL  reduces  CHD  event  rates  in  primary  prevention,  secondary
intervention, and angiographic trials. Generally speaking, for every 1% reduction in LDL,
there is a 1% reduction in CHD event rates. However, if treatment extends beyond the typical
duration of a clinical trial (2–5 years),the accumulated benefit could be greater. Elevations of
HDL of 1%result in approximately 2% reduction in CHD events. Although many efficacious
lipid-lowering drugs exist, none is effective in all lipoprotein disorders, and all such agents
are associated with some adverse effects.
                Lipid-lowering drugs can be divided broadly into agents that decrease the synthesis
of  VLDL  and  LDL,  agents  that  enhance  VLDL  clearance,  agents  that  enhance  LDL
catabolism, agents that decrease cholesterol absorption, agents that elevate HDL, or some
combination of these characteristics. Table1.3 lists recommended drugs of choice for each
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lipoprotein phenotype and alternate agents.
           Pharmacologic treatment of hyperlipidemia in conjunction with therapeutic lifestyle
changes can be used for both primary and secondary prevention of cardiovascular disease.
guidelines are available to help physicians manage hyperlipidemia (Table 1.4).44, 45, 46. These
guidelines  agree  that  therapeutic  lifestyle  changes  are  the  mainstay  of  hyperlipidemia
management, and that LDL cholesterol should be the primary target of therapy. Treatment of
hyperlipidemia improves outcomes for patients with known coronary heart disease (CHD) or
the risk equivalent, and for high-risk patients (i.e., those with a 10 year CHD risk of greater
than 20 percent) without known CHD or the risk equivalent.
                 The evidence supporting treatment of hyperlipidemia for primary prevention is
inconsistent. Patients with the highest baseline risk are most likely to benefit. Medications
should be chosen based on a favorable balance between the likelihood of  benefits  (e.g.,
patient-oriented outcomes, mortality, CVD events, functional status, quality of life) and harm
(adverse  effects),  as  well  as  cost.47Table  1.5summarizes  medications  used  to  treat  lipid
disorders48
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Risk category LDL cholesterol goal
Drug therapy
recommendations
 High risk CHD or 
risk equivalent 10-
year CHD risk > 20 
percent
<  100  mg  per  dL  (2.59
mmol per L)
Optional goal of < 70 mg
per dL (1.81 mmol per L)
is  favored  in  patients  at
very high risk (CHD plus
multiple major or poorly
controlled risk factors)
Initiate if LDL cholesterol
is ≥ 100 mg per dL
Consider if level is < 100 mg
per dL‡
 Moderately  high
risk
≥ two risk factors§
10-year CHD risk of 10
to 20 percent
<  130  mg  per  dL  (3.37
mmol  per  L)Optional
goal < 100 mg per dL
Initiate if LDL cholesterol
is  ≥  130  mg  per  Dl.
Consider if level is 100 to
129  mg  per  dL  (2.59  to
3.34 mmol per L)
 Moderate risk
≥ two risk factors§
10-year  CHD risk  <  10
percent
Consider  if  LDL
cholesterol  is  ≥  160  mg
per dL (4.14 mmol per L)
 Low risk
One or no risk factors < 160 mg per dL
Consider if LDL cholesterol
is  ≥  190  mg  per  dL  (4.92
mmol per L)
 Low risk
One or no risk factors < 160 mg per dL
Consider if LDL cholesterol
is  ≥  190  mg  per  dL  (4.92
mmol per L)
Table 3:  National Cholesterol Education Program, Adult Treatment 
Lipoprotein Type Drug of Choice     CombinationTherapy
I
Not indicated ---
IIa
Statins
Niacin
Cholestyramine
Niacin or BAR
Statins or BAR
Ezetimibe
Statins or niacin
IIb Statins BAR or fibrates or niacin
III Fibrates Statins or niacin
IV Fibrates
Niacin
Niacin
Fibrates
V Fibrates
Niacin
Niacin
Fish oils
TREATMENT :
STATINS:
            Studies have evaluated statin therapy based on C-reactive protein level. The
JUPITER (Justification  for  the Use of  Statins  in  Prevention:  an Intervention Trial
Evaluating Rosuvastatin) study included participants with LDL cholesterol levels of
less than 130 mg per dL (3.37 mmol per L) and elevated high-sensitivity C-reactive
protein  levels  who  received  rosuvastatin  (Crestor)  or  placebo  for  two  years.56
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Table: 4:  Lipoprotein Phenotype and Recommended Drug Treatment
Treatment with statins as primary prevention should be offered to those at the highest
risk of developing CHD. No statin has been proven superior at preventing CHD and,
at equivalent doses, all statins substantially reduce LDL cholesterol57.
Medication Contraindications Effectiveness
1. Bileacid  binding
resins48
Contraindicated  in
complete  biliary  or
bowel obstruction 
Combined
primary/secondary
prevention: reduces relative
risk  of  cardiovascular
mortality by 30 percent 
Primarily  reduces  LDL
cholesterol  by  15  to  30
percent 
2.
Fibrates50,51 Contraindicated  in
severe hepatic or renal
disease 
No  effect  on  all-cause
mortality 
Combined
primary/secondary
prevention:  NNT  =  46  to
125 to prevent one coronary
event; NNT = 53 to 150 to
prevent  one  nonfatal
myocardial infarction
3.
HMG-CoA
reductase
inhibitors
(statins)52,53
Contraindicated  in
active  liver  disease
and pregnancy 
Primary prevention: NNT =
81 for four years to prevent
one coronary event; NNT =
244  for  four  years  to
prevent one cerebrovascular
event 
Secondary prevention: NNT
=  50  for  five  years  to
prevent one death 
Acute  coronary  syndrome:
NNT  =  77  treated  with
high-dose  statins  for  two
years to prevent one death
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4.
Nicotinic  acid
(niacin)54
Contraindicated  in
severe  peptic  ulcer
disease,  chronic  liver
disease,  and  severe
gout 
Does  not  affect  all-cause
mortality 
When  combined  with
statins,  improves  disease-
oriented outcomes‡ 
Primarily  increases  HDL
cholesterol  by  15  to  35
percent
5. Omega-3  fatty
acids55
Use  with  caution  in
patients  with  fish
allergy 
Secondary prevention: NNT
=  57  for  two  years  to
prevent  one  death  in
patients  with  previous
myocardial infarction; NNH
=  159  for  two  years
resulting  in  patients  with
angina  one  sudden  cardiac
death in
                                  Table 5: Drugs used in hyperlipidima
• PITAVASTATIN (LIVALO):
                 Pitavastatin is a new, synthetic member of the statin class of lipid-lowering
drugs. Compared with other available statins, it has a unique cyclopropyl group on its
base structure that  is  believed to increase 3-hydroxy-3-methylglutaryl  coenzyme A
reductase inhibition by a factor of five and to significantly increase the transcription
and  activity  of  LDL  receptors.  Pitavastatin  is  primarily  metabolized  via
glucuronidation and is  not a substrate for the cytochrome P450 3A4 enzyme,  thus
avoiding the potential for cytochrome P450-mediated drug-drug interactions. Clinical
trials  have shown that  pitavastatin is comparable to atorvastatin and simvastatin in
improving lipid measures, and more potent than pravastatin. Pitavastatin is effective in
reducing  triglycerides  and  increasing  HDL-cholesterol,  so  it  will  be  particularly
beneficial in treating patients with mixed dyslipidemia. Its safety and adverse event
profile is similar to that of other available statins, and it has an established history of
use in Asia indicating tolerability and safety for treatment lasting up to 7 years.
Indications and usage
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LIVALO is a HMG-CoA reductase inhibitor indicated for:
 Patients  with  primary  hyperlipidemia  or  mixed  dyslipidemia  as  an
adjunctive  therapy  to  diet  to  reduce  elevated  total  cholesterol  (TC),  low
density  lipoprotein  cholesterol  (LDL-C),  apolipoprotein  B  (Apo
B),triglycerides  (TG),  and  to  increase  high-density  lipoprotein
cholesterol(HDL-C) 
Warnings and precautions
 Skeletal  muscle  effects  (e.g.,  myopathy  and rhabdomyolysis):  Risks
increase  in  a  dose-dependent  manner,  with  advanced  age  ( 65),  renal
impairment,  and  inadequately  treated  hypothyroidism.  Advise  patients  to
promptly  report  unexplained  and/or  persistent  muscle  pain,  tenderness,  or
weakness, and discontinue LIVALO
 Liver  enzyme  abnormalities:  Persistent  elevations  in  hepatic
transaminases can occur. Check liver enzyme tests before initiating therapy
and as clinically indicated thereafter
Adverse reactions
 The most frequent adverse reactions (rate 2.0% in at least one marketed
dose) were myalgia, back pain, diarrhea, constipation and pain in extremity.
Primary Hyperlipidemia and Mixed Dyslipidemia
 LIVALO® is indicated as an adjunctive therapy to diet to reduce elevated
total  cholesterol  (TC),  low-density  lipoprotein  cholesterol(LDL-C),
apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C in adult
patients with primary hyperlipidemia ormixed dyslipidemia.58
• PRAVACHOL: 
PRAVACHOL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive
therapy to diet to: 
 Reduce the risk of MI, revascularization, and cardiovascular mortality in
hypercholesterolemic patients without clinically evident CHD 
 Reduce  the  risk  of  total  mortality  by  reducing  coronary  death,  MI,
revascularization, stroke/TIA, and the progression of coronary atherosclerosis
in patients with clinically evident CHD. 
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 Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase
HDL-C  in  patients  with  primary  hypercholesterolemia  and  mixed
dyslipidemia. 
 Reduce elevated serum TG levels in patients with hypertriglyceridemia. 
 Treat  patients  with  primary  dysbetalipoproteinemia  who  are  not
responding to diet.
 Treat  children  and  adolescent  patients  ages  8  years  and  older  with
heterozygous familial hypercholesterolemia after failing an adequate trial of
diet therapy. 
Limitations of use: 
 PRAVACHOL has not been studied in Fredrickson Types I and V
dyslipidemias. 
Indications and usage
 as an adjunct to diet to reduce elevated total cholesterol (Total-C),
low-density lipoprotein  cholesterol  (LDL-C),  apolipoprotein  B (ApoB),
and  triglyceride  (TG)  levels  and  to  increase  high-density  lipoprotein
cholesterol  (HDL-C) in patients with primary hypercholesterolemia and
mixed dyslipidemia (Fredrickson Types IIa and IIb).
 as an adjunct to diet  for the treatment of patients with elevated
serum TG levels (Fredrickson Type IV). hypercholesterolemia (HeFH) in
children  and  adolescent  patients  ages  8  years  and  older  if  there  is  a
positive family history of premature cardiovascular disease (CVD).
Contraindications
 Hypersensitivity to any component of this medication
 Active liver disease or unexplained, persistent elevations of serum
transaminases.
  Women who are pregnant or may become pregnant.
 Nursing mothers. 
Adverse reactions
 In short-term clinical trials, the most commonly reported adverse
reactions  (≥2%  and  >  placebo)  regardless  of  causality  were:
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musculoskeletal  pain,  nausea/vomiting,  upper  respiratory  infection,
diarrhea, and headache. 
Therapy  with  PRAVACHOL (pravastatin  sodium)  should  be  considered  in  those
individuals at increased risk for atherosclerosis-related clinical events as a function of
cholesterol  level, the presence or absence of coronary heart disease,  and other risk
factors 59
TRILIPIX (FENOFIBRIC ACID): 
Trilipix (fenofibric acid) is a lipid regulating agent available as sustained/quick-release
tablet  formulation  for  oral  administration.  Trilipix  activates  the  peroxisome
proliferator  activated receptor  a  (PPARa) and affect  the expression of  target  genes
involved in cell  proliferation,  cell  differentiation and in immune and inflammation
responses. Trilipix as an adjunct to diet is specifically indicated for 60: 
Indications and usage
FIBRICOR  is  a  peroxisome  proliferator  receptor  alpha  (PPAR-alpha)  activator
indicated:
 To  reduce  triglyceride  (TG)  levels  in  patients  with  severe
hypertriglyceridemia (>500 mg/dl)
 To reduce elevated total cholesterol (TC), low-density-lipoprotein
cholesterol  (LDL-C),  TG  and  apolipoprotein  (Apo)  B  and  to  increase
high-density  lipoprotein  cholesterol  (HDL-C)  in  patients  with  primary
hyperlipidemia or mixed dyslipidemia 
General Considerations for Treatment: 
 The active  moiety of  FIBRICOR is  fenofibric  acid.  The
pharmacological effects of fenofibric acid have been extensively
studied  through  oral  administration  of  fenofibrate,  which  is
converted in vivo to fenofibric acid 
Limitations of use: 
 Fenofibrate as a dose equivalent to 105 mg of FIBRICOR
was  not  shown to  reduce  coronary heart  disease  morbidity  and
mortality in a large,  randomized controlled trial of patients with
type 2 diabetes mellitus
Contraindications 
 Severe renal dysfunction, including patients receiving dialysis 
 Active liver disease 
Department of Pharmacology Page 22
 Gallbladder disease 
 Nursing Mothers 
 Known hypersensitivity to fenofibric acid or fenofibrate 
Warnings and precautions 
 Fenofibrate can increase serum transaminases. Monitor liver tests
periodically
 Fenofibrate increases cholesterol excretion into the bile, leading to
risk of cholelithiasis. If cholelithiasis is suspected, gallbladder studies are
indicated 
 Exercise  caution  in  concomitant  treatment  with  oral  coumarin
anticoagulants. Adjust the dosage of coumarin anticoagulant to maintain
the  prothrombin  time/INR  at  the  desired  level  to  prevent  bleeding
complications 
 Myopathy  and  rhabdomyolysis  have  been  reported  in  patients
taking fenofibrate. The risks of myopathy and rhabdomyolysis appears to
be increased in elderly patients and patients with diabetes, renal failure, or
hypothyroidism 
 Fenofibrate  can  reversibly  increase  serum  creatinine  levels.
Monitor renal function periodically in patients with renal insufficiency 
Adverse reactions:
 Most common adverse reactions (> 2% and greater than placebo)
are increased liver tests, abdominal pain, back pain, and headache.
Primary Hyperlipidemia or Mixed Dyslipidemia:
 FIBRICOR is  indicated  as  adjunctive  therapy to  diet  to  reduce
elevated  LDL-C,  Total-C,  TG,  and  Apo B,  and to  increase  HDL-C in
hypercholesterolemia or mixed dyslipidemia patients with primary
Co-administration Therapy with Statins for the Treatment of Mixed Dyslipidemia 
1) Treatment of Severe Hypertriglyceridemia 
2) Treatment of Primary Hyperlipidemia or Mixed Dyslipidemia 
• FENOFIBRATE: 
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         Fenofibrate is an enhanced sustained/quick-release tablet formulation of the
PPAR alpha agonist fenofibrate formulated with the company's Melt Dose technology.
Through  PPAR  activation  that  fenofibrate  increases  lipolysis  and  elimination  of
triglyceride-rich  particles  from  plasma.  This  results  in  fall  in  triglycerides  which
ultimately produces an alteration in the size and composition of LDL. The synthesis of
apoproteins A-I, A-II and HDL-cholesterol is induced by activation of PPAR alpha 61. 
Dose:  The  recommended  initial  dose  of  the  drug  for  hyperlipidemia  and  mixed
dyslipidemia  is  120  mg  per  day.  The  recommended  initial  dose  for
hypertriglyceridemia is 40 to 120 mg per day. The maximum dose is 120 mg per day. 
Treatment Area: hyperlipidemia, dyslipidemia and hypertriglyceridemia 
OTHER HYPOLIPIDEMIC DRUGS: 
• EZETIMIBE: 
         It a new drug that acts by inhibiting intestinal absorption of cholesterol and
phytosterols. It interferes with a specific CH transport protein NPC1C1 present in the
interstinal mucosa and reduces absorption of both dietary and biliary CH. Even after
the compensatory increase in hepatic CH synthesis, LDL-CH level is lowered by 15-
20%. 
Pharmacokinetics:  Due to its poor aqueous solubility, ezetimibe is not absorbed as
such.  It  is  absorbed  partly  agter  getting  conjugated  with  glucuronic  acid  in  the
intestinal mucosa which gets secreted in bile and undergoes entero hepatic circulation
and excreted in faeces62. 
• GUGGAL LIPIDS: 
It  is  a  ayurvedic  preparation  which  is  a  mixture  of  sterones  obtained  from “gum
guggal”. 
Modest lowering of plasma CH and TG’s occurs after continued use of gugulipids63. 
A.D.R: Loose stools are only significant side effects.
FDA Approved drugs64: 
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• Efient  (prasugrel);  Eli  Lilly;  for  the  prevention  of  thrombotic
cardiovascular complications in acute coronary syndromes, Approved July
2009 
• Livalo  (pitavastatin);  Kowa  Company;  For  the  treatment  of
primary hyperlipidemia and mixed dyslipidemia, Approved August 2009 
• Trilipix (fenofibric acid); Abbott Laboratories; For the treatment of
dyslipidemia,  hypertriglyceridemia  and  hyperlipidemia,  Approved
December 2008 
• Crestor (rosuvastatin calcium); AstraZeneca; For the treatment of
primary hypercholesterolemia (heterozygous familial and nonfamilial) and
mixed dyslipidemia, Approved August 2003 
• Altocor (lovastatin) Extended-Release Tablets; Andrx; Oral tablets
for the adjuctive treatment of hypercholesterolemia, Approved June 2002 
• Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
For  the  use  as  an  adjunct  to  diet  to  reduce  elevated  total  cholesterol,
Approved October 2000 
• Lescol (fluvastatin sodium) capsules, Rx; Novartis; Treatment for
the reduction of triglycerides, Approved June 1999 
• Tricor (fenofibrate); Abbott Laboratories; Treatment for very high
triglyceride levels, Approved February 1998 
• Zocor;  Merck;  Treatment  for  high  cholesterol,  Approved
November 1997 
• Plavix  (clopidogrel  bisulfate);  Sanofi-aventis,  Bristol-Myers
Squibb; Treatment for cardiac atherosclerotic events, Approved November
1997.
• Pravachol (pravastatin sodium); Bristol-Myers Squibb; Treatment
for cholesterol-lowering, Approved July 1996.
Department of Pharmacology Page 25
.Chapter: II
Review of Literature
Department of Pharmacology Page 26
  
                                  
                                      II. REVIEW OF LITERATURE
• Santhan  S  et.al   reported  The anti-diabetic  and  nephroprotective  activity  of  the
Ethanolic extract of the whole plant of  Canthium dicoccum (family: rubiaceae) was
investigated on alloxan induced  diabetic  albino  rats.  Alloxan induced  diabetic  rat
model  and oral  glucose tolerance test  (OGTT) model  was used for  evaluation of
antidiabetic  activity.  The  biochemical  parameters  were  analysed.  All  rats  in  the
diabetic groups had FBG levels well within the diabetic range (>150 mg dL-1) at the
initial  stage  of  the  experiment  but  after  21  days  of  treatment  with  extracts  or
glibenclamide the FBG significantly dropped in dose-dependent manner.
• Bhaargavi vuyyuri  Et.al  reported  Ethanolic extract  of Canthium dicoccum whole
plant was studied for its Anti-inflammatory activity in various animal experimental
models. The plantextract  at  doses  250mg/kg and 500mg/kg significantly inhibited
inflammation  at  P<0.05  in  allthe  experimental  models.  Test  dose  at  500mg/kg,
offered  more  protection  against  inflammationwhen  compared  to  standard  in
carrageenan  paw  oedema  model.  In  the  formalin  induced  model  aprogressive
inhibition  of  inflammation  from  the  4th  day  was  observed  with  both  the
studycompound and the standard Diclofenac.
• B. Murali  reddy1 et  al   reported  Evaluation of anti-arthritic activity of ethanolic
extract of canthium dicoccum in albino rats the observed anti-arthritic activity may be
due  to  the  presence  of  phytoconstituents  such  as  tri-terpenoids  and  flavonoids.
Biochemical parameters such as serum parameters sgot, sgpt, alp, for assessing the
anti- arthritic potential of ethanolic extract of canthium dicoccum. Authors concluded,
ethanolic  extract  of  canthium dicoccum  possess  a significant  anti-arthritic  activity
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against  egg-albumin  induced  arthritis  model  and  justifying  its  therapeutic  role  in
arthritic condition .
• Herath et  al  reported  Alkaloidal  and other  constituents  of  Uncaria  elliptica and
canthium  dicoccum.  A new  alkaloid  roxburghine  X,  along  with  roxburghine  D,
formosanine and mitraphylline, has been isolated from the bark of Uncaria elliptica.
Sitosterol, quinovaic acid, acetylquinovaic acid and scopoletin were isolated from the
bark of Canthium dicoccum.
• Gunasegaran R  et.al reported flavonol glycoside, characterized as 7-O-(6-O-benzoyl-
beta-D-glucopyranosyl)-rutin  (1),  has  been  isolated  from the  leaves  of  Canthium
dicoccum. Detailed 1H COSY, HSQC, HMBC and TOCSY NMR as well as positive
and negative electro spray MS and MS/MS data have been provided for the new
compound.
• Raja rajeswari et.al reported   GC-MS analysis of bioactive components from the
ethanolic  leafextract  of  canthium  dicoccum  (gaertn.)  teijsm  &  binn.the  major
chemical  constituentsare  spathulenol  (20.76  %),  caryophyllene  oxide  (19.25  %),
cedren-13-ol (10.62 %), ledeneoxide (5.24 %), m-mentho-4, 8-diene (6.41 %) and 2-
furancarboxaldehyde  (4.51  %).  thus  theextract  of  canthium  dicoccum  was
characterized  by  substantial  levels  of  sesquiterpenoids  (55.87%),  nitrogenous
compounds (12.93 %), aldehydes (8.7 %), terpinolene (6.41 %) and phenols(4.26 %).
the  presence  of  some  of  these  constituents  in  the  plant  extract  provides  the
scientificevidences  for  the  antimicrobial,  anti-tumor,  immuno  modulatory  and
antioxidant properties ofthe plant.
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Work    
                             III. SCOPE, OBJECTIVE AND PLAN OF WORK
        Hyperlipidemia  is a major problem associated as a risk factor for atherosclerosis
and other  ailments  like  Coronary  heart  disease  (CHD),  Ischemic  cerebro vascular
disease, Peripheral  vascular  disease,  Obesity,  Diabetes  and leads  to oxidative stress
and lifestyle habits such as consumption of alcohol, smoking which are currently the
leading cause  of  illness  and death  in  developed countries  and will  soon  become
the pre-eminent health problem as it is also faced by the youth worldwide. 
                 The present lipid lowering agents i.e. all statins and other lipid lowering
agents  are  expensive  and has  more  pronounced adverse  effects  which  may
include   hypothyroidism, renal insufficiency, hepatic dysfunction. Hence, need for
safer drugs  with reduced toxicity are still in research. 
          Traditional medicines serves to have a rich source of medicinal herbs for
various  diseases  which  are  relatively  safe  compared  to  synthetic  chemical  drugs
available  in the  market.  Past few decades studies  on  herbal  medicine  and plants
has  gained  importance throughout the world. Discovery of pharmacologically active
constituents  from  the  natural  products  are  made.  Particularly for  the  disease
where  the   present   range  of  drugs  are  less  effective  or  has  pronounced  adverse
effects.  To the best  of  knowledge this is  the first  study investigating the effect  of
Canthium dicoccum in the lipid profiles in high fat diet induced rats
OBJECTIVES OF THE STUDY:
           The objective of the study is to investigate the Hypolipidemic Activity of
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Ethanolic  extract  of  Canthium  dicoccum on  Triton-X  and  High  Fat  Diet  induced
Hyperlipidemia in Albino Rats. 
Study was conducted with following objectives.
    
 PLAN OF WORK:
1. Identification, Collection and processing of plant species. 
2. Extraction, concentration purification and formulation of extract. 
3.    Toxicity studies acute toxicity (OECD 423) 
     4.    Evaluation of Hypolipidemic Activity of Ethanolic extract of Canthium 
dicoccum on    Triton-X100 and High Fat Diet induced Hyperlipidemia in 
Albino Rats
 Selection of animal
 Induction of hyperlipidimia 
 Experimental design
 Collection of blood 
 Biochemical evaluation parameters  
 Total cholesterol 
 Triglycerides
 LDL
 HDL 
 VLDL
 Athreogenic index 
 Statistical analysis
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Chapter: IV
Plant profile    
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                                             IV. PLANT PROFILE
Canthium dicoccum:
           Medicinal plants are sources of important therapeutic aids for alleviating
human  ailments.  Canthium  dicoccum is  one  of  the  medicinally  important  plants
belonging to the family Rubiaceae, commonly known as “Nallamandharam” in Tamil.
                                                       Canthium dicoccum
Description:
Title of plant :          Canthium dicoccum
Family                  :          Rubiaceae
Synonyms             :  Plectronia didymium (Gaertn), Canthium didymum
Parts used             :         Whole plant
Habitat                  :         India.
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Botanical descriptions:
Habit           : Trees up to 12 m tall.
Trunk\bark : Bark grey, smooth, irregularly fissured and flaky when mature; blaze cream.
Branchlets   : Young branchlets usually quadrangular, glabrous.
Leaves : Leaves simple, opposite, decussate; stipules interpetiolar linear with  broad
base,  to  0.9  cm  long; petiole 0.6-1  cm  long, planoconvex in  cross
section, glabrous; lamina 6-15  x  2.5-7  cm, elliptic, apex acuminate,
base cuneate,margin entire, coriaceous,shiningabove, glabrous beneath;midrib 
raisedabove; secondary_nerves 4to7pairs, domatia present  at  axills; tertiary
nerves obscure.
Flowers         : Inflorescence axillary cymes.
Fruit& seed  : Drupe ovoid; pedicel 1.5 cm long.
Ecology:
Understorey trees in evergreen to semi-evergreen forests upto 1900 m.
Distribution :
Indomalaysia and China; in the Western Ghats- throughout.65
                       Canthium dicoccum is found in Western Ghats of India. The common
names in Tamil  are Nanjul, Nallamandharam and in Malayalam as Nanyul.  It  is a
medium sized  tree.  Trees  grow upto  10  m,  leaves  oblanceolate,  glabrous,  shortly
acuminate at apex, margin entire, truncate at base;stipules triangular. Fruits are edible.
The plants are common in dry-deciduous forests. Plant possesses antipyretic activity.
In India, bark is used as febrifuge and also applied as plasters. The decoction of roots
is used internally for treating diarrhoea. Bark powder boiled with sesame oil is used
externally for rheumatic pains  66.It is a much branched glabrous shrub or small tree,
cultivated for its leaves although stem bark, roots, flowers and seeds have also been
used in traditional medicine. The plant is reported to contain, flavonoids, tannins and
phenolic compounds, terpenoids, quinones, coumarins, and glycosides. The plant has
been  reported  to  have  analgesic,  antipyretic,  diarrhea,  rheumatic  pains,  anti-
inflammatory,  antifungal,  bone  fractures,  and  bark  is  used  as  febrifuge  and  also
applied as plasters.67
              Based on above said ethno-medical uses and chemical constituent in the
plant, the present work would be done to evaluate Hypolipidemic activity of Ethanol
Department of Pharmacology Page 34
extract of Canthium dicoccum using albino Wister strain rats as experimental animals.
       Chapter: V
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                  Materials  
and Methods         
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 s
                            V. MATERIALS AND METHODS
• MATERIALS :
• Collection of Plant material and authentification:
                 Plant material: The plant of  Canthium dicoccum plants were
collected from the certified ayurvedic wholesaler. The plant was identified and
authenticated by Asst Prof. K. Dr. K. Madhava chatty, MSc, Med, Department
of Botany, S.V. University, Tirupati
 Drugs 
Triton  x 100(Hi  media,  Mumbai),  Cholesterol  (SRL Mumbai),  Atorvastatin
(Micro labs Pvt Ltd, B, lore) Cholic acid (SRL, Mumbai) 
 Chemicals- 
Anaesthetic  ether-SD  Finechem  Ltd.,  Mumbai,Chloroform-SD  Finechem
Ltd .Mumbai.Formaline-SD Finechem Ltd., Mumbai and  all other chemicals
and reagents were of analytical grade.
  Diagnostic kits: 
 Diagnostic kits used for estimation ofcholesterol, triglycerides, HDL, LDL,
VLDL,  SGOT,  SGPT,  Total  protein  and  glucosewere  procured  from
Robonik Diagnostic Ltd India. 
 Instruments:
 Autoanalyzer  (Robonik),Refrigeratorcentrifuge(MPW-350R),UV-Spectro-
photometer (UV-1601, Shimadzu Corporation, Kyoto, Japan), Mini Lyotrap
(LTE Scientific  Ltd.),  Research centrifuge (Remi industries,  Mumbai)  and
homogenizer  (Remi  Motors,  Mumbai).  Dhona  balance  (M/S  Dhona
instruments Pvt. Ltd., Kolkata, India).
 Experimental Animals:
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        Wister albino of either sex (150–220 g) was obtained from the central
animal house of Sigma Institute of Clinical Research and administration Pvt
Ltd Hyderabad.  The animals were housed at room temperature (22-28 ºC)
for 12 hr dark and 12 hr light cycle and given standard laboratory feed and
water ad-libitum. The study was approved and conducted as per the norms of
the Institutional Animal Ethics Committee (769/2010/CPCSEA).
 Acute toxicity study
          Acute toxicity studies were performed according to OECD-423guidelines
category IV substance (acute toxic class method). Swiss albino mice (n=3) of either
sex  selected  by  random sampling  technique  were  employed  in  this  study.  The
animals were fasted for 4 hrs with free access to water only. The plant extracts of
Canthium dicoccum were administered orally with maximum dose of 2000 mg/kg
body weight. The mortality was observed for three days. If mortality was observed
in2/3 or 3/3 of animals, then the dose administered was considered as a toxic dose.
However, if the mortality was observed only one mouse out of three animals then
the same dose was repeated again to confirm the toxic effect. If mortality was not
observed,  the  procedure  was  then  repeated  with  higher  dose  (Organization  for
economic Co-operation and development, 2001).68
 Observations  
      Animals  were  observed  individually  at  least  once  during  the  first  30
minutes  after dosing, periodically during the first 24 hours (with special attention
given during the first  4  hours)  and daily thereafter,  for  a  total  of  14 days.  All
observations  were  systematically  recorded  with  individual  records  being
maintained for each animal.  Observations included changes in skin, mortality and
general  behavioral  pattern.   Attention  was  given  for  observations  of  tremors,
convulsions,  salivation,  diarrhoea,  lethargy,  sleep  and  coma.  No  death  was
observed till the end of study.
    
METHODOLOGY:
 Collection of Plant material and authentification:
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Plant material: The plant of Canthium dicoccum plants were collected from
the  certified  ayurvedic  wholesaler.  The  plant  was  identified  and
authenticated  by  Asst  Prof.  K.  Dr.  K.  Madhava  chatty,  MSc,  Med,
Department of Botany, S.V. University, Tirupati
 Preparation of extract: 
       The collected fresh plant materials were dried in shade (2 days) and then dried
in a hot air oven at 25ºC for three days and they were made in to coarse powder
with the use of mixer grinder. The powder of  Canthium dicoccum  obtained were
weighed separately and transferred to a round bottomed flask and then went to
continuous heat extraction with soxhlet apparatus using 95% ethanol for 24 hours.
Then  the  extract  of  ethanol  was  concentrated.  Extract  obtained  was  dried  by
placing it on a big petriplate on electric water bath (70ºC) and then kept in an oven
at 30ºC for 2 hour. The extract obtained was kept for drying and stored in vacuum
desiccators. The percentage yield of the extract was 7.5%.69
 Qualitative chemical test:  69
Preliminary phytochemical studies:  Ethanolic extract of the plant of  Canthium
dicoccum  were  subjected to  chemical  tests  for  the  identification of  their  active
constituents.
 Tests for carbohydrates and glycosides:
A small quantity of the extract was dissolved separately in 4 ml of distilled water 
and filtered.  The filtrate was subjected to Molisch’s test to detect the presence of 
carbohydrates.
A. Molisch’s Test
Filtrate was treated with 2-3 drops of 1% alcoholic α-naphthol solution and 2ml of
con.  H2SO4 was  added  along  the  sides  of  the  test  tube.  Appearance  of  violet
coloured  ring  at  the  junction  of  two  liquids  shows  the  presence  of
carbohydrates.Another  portion of  the  extract  was  hydrolysed  with  HCl  for  few
hours  on  a  water  bath  and   the  hydrolysate  was  subjected  to  Legal’s  and
Borntrager’s test to detect the presence of different glycosides.
B. Legal’s Test
To the hydrolysate, 1ml of pyridine and few drops of sodium nitroprusside solution
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were  added  and  then  it  was  made  alkaline  with  sodium  hydroxide  solution.
Appearance of pink to red colour shows the presence of glycosides.
C. Borntrager’s Test:
Hydrolysate  was  treated  with  chloroform  and  then  the  chloroform  layer  was
separated.   To  this  equal  quantity  of  dilute  ammonia  solution  was  added.
Ammoniacal layer acquires pink colour showing the presence of glycosides.
 Tests for alkaloids  : 
A small portion of the methanol extract was stirred separately with few drops of dil.
HCl and filtered.  The filtrate was treated with various reagents as shown for the
presence of alkaloids.
Mayer’s reagent  - Creamy precipitate 
Dragandroff’s reagent- Orange brown precipitate 
Hager’s reagent  - Yellow precipitate 
Wagner’s reagent - Reddish brown precipitate
 Tests for phytosterol
      The extract was refluxed with solution of alcoholic potassium hydroxide till
complete saponification takes place. The mixture was diluted and extracted with
ether. The ether layer was evaporated and the residue was tested for the presence of
phytosterol.
          Libermann Burchard Test:
The residue was dissolved in few drops of acetic acid, 3 drops of acetic anhydride
was added followed by few drops of con. H2SO4.  Appearance of bluish green
colour shows the presence of phytosterol.
 Tests for fixed oils :
 Spot test: 
Small  quantity  of  extract  was  separately  pressed  between  two  filter  papers.
Appearance of oil stain on the paper indicates the presence of fixed oil. Few drops
of 0.5N alcoholic potassium hydroxide were added to a small quantity of extract
along with a drop of phenolphthalein.  The mixture was heated on water bath for 1-
2 hours. Formation of soap or partial neutralization of alkali indicates the presence
Department of Pharmacology Page 40
of fixed oils and fats.
 Tests for gums and mucilages:
Small quantity of the extract was added separately to 25 ml of absolute alcohol
with constant stirring and filtered. The precipitate was dried in air and examined for
its swelling properties for the presence of gums and mucilages.
 Tests for Saponins:
The extract was diluted with 20 ml of distilled water and it was agitated in a 
graduated cylinder for 15 minutes.  The formation of 1cm layer of foam shows the 
presence of saponins.
 Tests for proteins and free amino acids:
Small quantity of the extract was dissolved in few ml of water and treated with
following reagents.
A. Millon’s reage Appearance of red colour shows the presence of protein   and free
amino acids.
B.  Ninhydrin reagent - Appearance of purple color shows the presence of   proteins
and free amino acids.
C.   Biuret  test  -  Equal  volumes of  5% NaOH solution and 1% coppersulphate
solution were added. Appearance of pink or purple colour shows the presence of
proteins and free amino acids.
 Tests for phenolic compounds and tannins:
Small  quantity  of  the  extract  was  taken  separately  in  water  and  tested  for  the
presence of phenolic compounds and tannins using following reagents.
A. Dil.FeCl3 solution (5%)                                                   -violet colour
B. 1% solution of gelatin containing 10% NaCl - white precipitate
C. 10% lead acetate solution - white precipitate.
 Tests for flavonoids:
A. With aqueous Sodium hydroxide solution:
Blue to violet colour (anthocyanins), yellow colour (flavones), yellow to orange   
(flavonones)
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B. With Con. H2SO4:
Yellow orange colour (anthocyanins), yellow toorange colour (flavones), orange 
to crimson (flavonones)
C. Shinoda’s test
Small quantity of the extract was dissolved in alcohol and to that a piece of 
magnesium followed by Con. HCl drop wise was added and heated.  Appearance of
magenta colour shows the presence of flavonoids.     
                              
EXPERIMENTAL MODELS FOR HYPERLIPIDEMIA :
Triton x 100 induced hyperlipidemia70
Thirty Wistar rats were randomly divided into 5 groups of 6 each. The group II to V
hyperlipidemia was induced in wistar albino rats by single intraperitoneal injection of
Triton x  100 (100mg/kg) in physiological saline solution after overnight fasting for 18
hrs. The first group was given standard pellet diet, water and orally administered with
5% CMC. The II to V group animals were injected i.p. with solution of Triton -x-
100mg /kg body weight. After 72 hours of triton injection, the second group received a
daily dose of 5% CMC (p.o) for 7 days. The third was administered with the standard
Atorvastatin 10mg/kg, p.o. for 7 days. IV and V group was administered a daily dose
of ECD 200 and 400 mg/kg suspended in 5% CMC, p.o., for 7 days, after inducing
hyperlipidemia.  Food was withdrawn 10h prior to the blood sampling. The first group
served as normal control. The different groups were assigned as described below.
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          Fig .Experimental design of Triton x 100 induced Hyperlipidemia in rats.
On the 8thday, blood was collected by retero-orbital sinus puncture,under mild ether
anaesthesia. The collected samples were centrifuged for 15 minutes at 2500rpm. Then
serum  samples  were  collected  and  analysed  for  serum  Total  Cholesterol
(TC),Triglycerides  (TG),  High  Density  Lipoprotein  Cholesterol  (HDL-C),Low
Density  Lipoprotein  Cholesterol  (LDL-C)  and  Very  Density  Lipoprotein
Cholesterol(VLDL-C)   serum  blood  glucose  and  atherogenic  index
(AI)71.Histopathological  analysis  of  liver  has  done.   Triglyceride,  cholesterol  and
HDL-C were  measured  with  enzymatic  kits.  LDL and  VLDL concentration  were
calculated from the Friedewald’s equation.
VLDL-C= TG/5
LDL-C ˗= TC  HDL- (TG/5)
AI was calculated by using the formula of Schulpis:
Atherogenic Index (AI):        TC- Total serum HDL-C
                                                 Total serum HDL-C
Induction of Hyperlipidemia by High Fat Died
            The rats were randomly assigned to five groups of six rats each and kept in
their cages for 5 days prior dosing to allow for acclimatization to laboratory condition.
The chronic hyperlipidemia produced by feeding cholesterol  1%, cholic acid 0.5%
suspended in 25% coccunut oil once a day for 28 days.. The feeding and treatment
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schedule  was  as  follows:
Fig.... Experimental design of High fat died induced Hyperlipidemia in rats.
On day 28th animals were anaesthetized with diethyl ether and blood was collected 
by retro-orbital punchure. The blood was subjected to centrifugation to obtain 
serum. Serum was analysed for TC, TG, HDL, LDL, VLDL and serum glucose. 
The histopathological analysis of aorta has done.
Biochemical Estimations:
Cholesterol72
Clinical significance
Measurement of serum cholesterol levels are useful in evaluation of the risk of the
coronary arterial occlusion, atherosclerosis, myocardial infarction , liver function,
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biliary function, intestinal absorption, thyroid function and adrenal disease.
Principle
The estimation of cholesterol involves the following enzyme catalyzed reactions.
Cholesterol ester    cholesterol + fatty acid
Cholesterol ester + O2   cholest-4-en-3one + H2O2
 H2O2 + 4AAP + phenol   4 H2O + Quinoneimine
CE: cholesterol esterase
CHOD: Cholesterol oxidase
4AAP: 4 aminoantopyrine
Calculation
                                    Abs. of test
Cholesterol (mg/dl) =                           × concentration of standard (mg/dl)
                                  Abs. of standard
Procedure:
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 10µl ……… ……..
Standard ……… 10 µl ……..
Sample ………. ……… 10 µl
Mix  well  after  each  addition  and  incubate  at  37°  C  for  10  minutes.  Read
absorbance ofstandard and test against reagent blank at 505/670 nm.
Increase
 Increased  levels  are  found  most  characteristically,  in  primary
hyperlipoproteinaemias
 In nephrotic syndromes
 -Myoxoedema
 Obstructive jaundice 
 Diabetes mellitus 
Decreases
 Low are frequently obtained in anemia 
 In hemolytic jaundice
 In malabsorption syndrome 
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CE
CHOD
POD
 severe malnutrition 
 Acute infections and in terminal state 
 Very low values occur in betalipoproteinemia and to a lesser degree in
familial hypobetalipoproteinaemias. 
Triglycerides73
Clinical significance
             Triglycerides are a family of lipids absorbed from the diet and produced
endogenously from carbohydrates. Measurement of triglyceride is important in the
diagnosis and management of hyperlipidemias. These diseases can be genetic or
secondary to other disorders including nephrosis, diabetes mellitus and endocrine
disturbances.  Elevation  of  triglycerides  has  been  identified  as  a  risk  factor  for
atherosclerotic disease.
Principle:
                                     Lipase
Triglycerides + H2O   Glycerol + Fatty acids
                            GK
       Glycerol + ATP                     Glycerol -3-phosphate + ADP
MG+2
                 GPO
Glycerol-3-Phosphate                              O2Dihydroxyacetone phosphate + H2O2
H2O2 + 4-aminoantipyrine + 3, 5-DHBS Quinoneimine + 3H2O
GK:  Glycerokinase
GPO: Glycerol 3 phosphate oxidase
DHBS: 3, 5-Dichloro-2-hydroxybenzene sulfonate
Lipase  hydrolysis  serum  triglycerides  to  glycerol  and  fatty  acids.  The
liberate glycerol is converted to glycerol-3-phosphate in the presence of ATP and
glycerokinase. Glycerol-3 phosphate is oxidised by glycerol 3 phosphate oxidase to
yield  H2O2.  H2O2 thus  generated  reacts  with  4-aminophenazone  and  4-
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chlorophenol  under  the  catalytic  influence  of  peroxidase  to  form  coloured
quinoneimine  complex.  The intensity of  colour  so  developed  is  proportional  to
triglyceride concentration and is measured at 505 nm.
Procedure
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 10µl ……… ……..
Standard ……… 10 µl ……..
Sample ………. ……… 10 µl
Mix and incubate for 10 minutes at 37° C. Read absorbance of standard and test
against reagent blank at 505 (500-540 nm).
Calculation
                                       
                                            Abs. of test
Triglycerides (mg/dl) =                                 × concentration of standard (mg/dl)
                                         Abs. of standard
  
HDL-Cholesterol74
Clinical significance
High density lipoprotein (HDL) contains particles of different density including lipid
and highest concentration of proteins amongst the different lipoproteins. Includes free
and esterified cholesterol, triglycerides, phospholipids and apoproteins A, C and E.
HDL cholesterol  values  are about  1/5th of  the total  cholesterol  values  and can  be
expressed as percentage of total cholesterol.
Decreases
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There  exists  an  inverse  relationship  between  HDL cholesterol  and  coronary heart
diseases. Low concentration i.e. below 30 mg/dl is one of the risk factors for cardiac
ailments.
Principle
Chylomicrons,  LDL  and  VLDL (low  and  very  low  density  lipoproteins)  are
precipitated from serum phophotungstate in the presence of divalent cat ions such
as magnesium. The HDL cholesterol remains unaffected in the supernatant and is
estimated using Robonik cholesterol reagent.
                               Phophotungstate
Serum/plasma=                                HDL + (LDL + VLDL + chylomicrons)
                             Mg2+       (Supernatant)               (Precipitate)
Procedure:
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 10µl ……… ……..
Standard ……… 10 µl ……..
Sample ………. ……… 10 µl
Mix well and allow the reaction mixture to stand for 10 min at R.T. centrifuge at
4000 rmp for 10 min to obtain clear supernatant. Use the supernatant to obtain
the concentration of HDL cholesterol in the sample.
Calculation
.                                      Abs. of test       
HDL (mg/dl) =                             x Concen of standard (mg/dl)x Dilution factor
                          Abs. of standard
Glucose75
‟Glucose estimation by Trinder s method 
Clinical significance
Accurate measurement of glucose in body fluids is important in the diagnosis
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and management of diabetes, hypoglycaemia, adrenal dysfunction and various
other conditions.
Principle
Glucose in sample is oxidized to yield gluconic acid and hydrogen peroxide in
the presence of glucose oxidase.The enzyme peroxidase catalyses the oxidative
coupling  of  4aminoantipyrine  with  phenol  to  yield  a  coloured  quioneimine
complex,  with  absorbance  proportional  to  the  concentration  of  glucose  in
sample.
                              Glucose oxidase
Glucose+O2+H2O                             Gluconic acid +H2O2
H2O2+Phenol+4AAP                          Quinoneimine dye +2H2O
Procedure
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 10µl ……… ……..
Standard ……… 10 µl ……..
Sample ………. ……… 10 µl
Increases
 Diabetes mellitus
 In patients receiving glucose containing fluids intravenously, during severe 
stress and cerebrovascular accidents. 
Decreases
 On insulin administration, as a result of insulinoma
 In born errors of carbohydrate metabolism or on fasting.
Histopathological studies:
At the end of the study period, animals from all the five groups were sacrificed
and liver was dissected out, washed, 5µm thick section slides were prepared and
stain with heamatoxyline-eosin and examined by light microscopy.
Statistical analysis
All the data expressed as mean SEM will  evaluated by one-way analysis  of
variance  (ANOVA),  followed  by  Dunnett’s  multiple  comparisons  test  using
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Prism Graphpad version 5.0 and values of P<0.05 will considered as statistically
significant.
Chapter: VI
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              Results
VI. RESULTS
Department of Pharmacology Page 51
Percentage yield of plant extract:
 The yield obtained from the ethanolic extract of Canthium dicoccum was about 162
grams (13.5 %) from 1.2 kg plant.
Identification of phytochemical analysis:
Phytoconstituents Presence or Absence
AbsentCarbohydrates +
Glycosides +
Fixed oils and fats +
Gums & mucilage -
Potein & amino acids -
Saponins +
Tannins +
Phytosterols ++
Flavonoids +++
Alkaloids ++
                                            Presence: +, Absence: -
I - TRITON-X-100 INDUCED HYPERLIPIDEMIA
1. Effect of ethanolic extract of Canthium dicoccum on serum lipid profile, 
glucose level and atherogenic index in Triton x induced hyperlipidaemia in rats.
1. Effect on serum Total cholesterol level
Rats given with triton x 100 intraperitoneal injection had increased serum TC level
(132.2±2.76) when measured on 8 day. This was significantly higher (p<0.001) when
compared to serum TC levels in normal control rats.
Triton x 100 animals treated with Atorvastatin (10mg/kg, p.o. once daily) had serum
TC level  of  (88.49±0.33)  when  measured  on  day 7.  This  was  significantly  lower
(p<0.001)  when  compared  to  serum  TC  levels  in  control  (Triton  x  100)  rats
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(132.2±2.76).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had serum
level of (98.15±8.32and 86.50±6.83) when measured on day 8. These values  were
significantly lower (p<0.001 and p<0.001) when compared  to  serum TC levels  in
control (Triton x 100) rats (132.2±2.76).
2. Effect on sermTriglycerides level
Rats given with triton x 100 intraperitoneal injection had increased serum TC level
(109.3±1.76) when measured on 8 day. This was significantly higher (p<0.001) when
compared to serum TG levels in normal control rats (85.89±0.28).
Triton x 100 animals treated with Atorvastatin (10mg/kg, p.o. once daily) had serum
TG level  of  (74.33±0.59)  when  measured  on  day 8.  This  was  significantly lower
(p<0.001)  when  compared  to  serum  TG  levels  in  control  (Triton  x  100)  rats
(109.3±1.76).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had serum
TG level  of  (81.00±0.48and  77.23±0.53)  when  measured  on  day 8.  These  values
weresignificantly lower (p<0.001 and p<0.001) when compared to serum TC levels in
control (Triton x 100) rats (109.3±1.76).
3. Effect on serum HDL-C level
Rats given with triton x 100 intraperitoneal injection had increased serum HDL level
(52.19±4.96) when measured on 8 day. This was significantly lower (p<0.01) when
compared to serum HDL levels in normal control rats (71.15±0.77).
Triton x 100 animals treated with Atorvastatin (10mg/kg, p.o. once daily) had serum
HDL level of (67.95±3.57) when measured on day 8. This was significantly higher
(p<0.01)  when  compared  to  serum  HDL  levels  in  control  (Triton  x  100)  rats
(52.19±4.96).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had serum
HDL level  of  (57.57±4.19 and 66.09±2.46) when measured on day 8.  The extract
200mg/kg was showed no significant changed and 400mg/kg was significantly higher
p<0.05  when  compared  to  serum  HDL  levels  in  control  (Triton  x  100)  rats
(52.19±4.96).
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4. Effect on serum LDL-C level
Rats given with triton x 100 intraperitoneal injection had increased serum LDL level
(18.40±4.79) when measured on 8 day. This was significantly higher (p<0.001) when
compared to serum LDL levels in normal control rats (4.167±0.84).
Triton x 100 animals treated with Atorvastatin (10mg/kg, p.o. once daily) had serum
LDL level of (5.683±3.69) when measured on day 8. This was significantly lower
(p<0.01)  when  compared  to  serum  LDL  levels  in  control  (Triton  x  100)  rats
(18.40±4.79).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had serum
LDL level of (24.38±8.58 and 15.97±2.93) when measured on day 8. These values
were showed no significant  changed in LDL level  when compared to  serum LDL
levels in control (Triton x 100) rats (18.40±4.79).
5. Effect on serum VLDL-C level
Rats given with triton x 100 intraperitoneal injection had increased serum VLDL level
(21.88±0.36) when measured on 8 day. This was significantly lower (p<0.001) when
compared to serum VLDL levels in normal control rats (17.15±0.04).
Triton x 100 animals treated with Atorvastatin (10mg/kg, p.o. once daily) had serum
VLDL level of (14.87±0.12) when measured on day 8. This was significantly lower
(p<0.01)  when  compared  to  serum  VLDL levels  in  control  (Triton  x  100)  rats
(21.88±0.36).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had serum
VLDL level of (16.20±0.10 and 15.47±0.09) when measured on day 8. These values
were significantly lower (p<0.01 and p<0.001) when compared to serum VLDL levels
in control (Triton x 100) rats (21.88±0.36).
6. Effect on serum glucose level
Rats given with triton x 100 intraperitoneal  injection had increased serum glucose
level (146.0±12.59) when measured on 8 day. This was significantly higher (p<0.001)
when compared to serum glucose levels in normal control rats (68.21±2.10).
Triton x 100 animals treated with Atorvastatin (10mg/kg,p.o. once daily) had serum
glucose level of (99.99±8.87) when measured on day 8. This was significantly lower
(p<0.01)  when  compared  to  serum  glucose  levels  in  control  (Triton  x  100)  rats
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(146.0±12.59).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had serum
glucose  level  of  (104.0±9.03and 101.6±9.61)  when  measured  on  day 8.  This  was
significantly lower (p<0.05 and p<0.01) when compared to serum glucose levels in
control (Triton x 100) rats (146.0±12.59).
8. Effect on AI
Rats given with triton x 100 intraperitoneal injection had increased atherogenic index
(0.85±0.19)  when  measured  on  8thday.  There  was  no  significant  increased  AI  in
control when compared to AI in normal control rats (0.31±0.01).
Triton x 100 animals treated with Atorvastatin (10mg/kg, p.o. once daily) had AI of
(0.31±0.09) when measured on day 8.  This was significantly lower (p<0.01) when
compared to AI in control (Triton x 100) rats (0.85±0.19).
Triton x 100 animals treated with extract 200 and 400mg/kg p.o. once daily had AI of
(0.91±0.24 and 0.53±0.21) when measured on day 8. These values were exhibited no
significantly lower AI when compared to AI in control (Triton x 100) rats (0.85±0.19).
ACUTE TOXICITY STUDIES :
The ethanolic extract of Canthiumdicoccumon has not shown any changes in autonomic
or motor behavioral changes in rats. Also no death is seen upto 2000mg/kg of the extract.
SL NO CLINICAL SIGN
PARAMETERS
                                 OBSERVATION 
UPTO 4 HRS 14 TH DAY 
1. Changes in skin and 
fur 
No change No change 
2. Lacrimation Absent Absent 
3. Urine stain Absent Absent 
4. Diarrhoea Absent Absent 
5. Pilo erection Absent Absent 
6. Straubs tail Absent Absent 
7. Grip strength Present Present 
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8. Convulsion Absent Absent 
 9. Circling movement Absent Absent 
10. Lethargy Absent Absent 
11. Tremors Absent Absent 
12. Apnea Absent Absent 
13. Grooming Absent Absent 
14. Rearing Absent Absent 
15. Writhing Absent Absent 
16. Loss of righting 
reflex 
Absent Absent 
17. Mortality No death No death 
 
Treated 
groups Serum Lipid profile and Glucose mg/dl
TC mg/dl TG mg/dl HDL mg/dl LDL mg/dl VLDL mg/dl Glucose 
mg/dl
Sham 
operated 
Normal
92.48±0.40 85.89±0.28 71.15±0.77 4.167±0.84 17.15±0.04 66.44±2.15
Control 
(Triton X 100)
132.2±2.76a 109.3±1.76a 52.19±4.96b 18.40±4.79a 21.88±0.36a 146.0±12.59a
Standard 
(ATS 
10mg/kg)
88.49±0.33*** 74.33±0.59*** 67.95±3.57* 5.683±3.69** 14.87±0.12** 99.99±8.87**
ECD 
200mg/kg
98.15±8.32*** 81.00±0.48*** 57.57±4.19ns 24.38±8.58ns 16.20±0.10** 104.0±9.03*
ECD 
400mg/kg
86.50±6.83*** 77.23±0.53*** 66.09±2.46* 15.97±2.93ns 15.47±0.09*** 101.6±9.61**
 Table: . Effect of ethanolic extract of Canthiumdicoccumon serum lipid profile and 
serum glucose level in triton x induced hyperlipidemia inrats.
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by  multiple  comparision  of  Dunnett’s  test,*p<0.05,**p<0.01,  ***p<0.001  as
compared to control and ap<0.001,bp<0.01 as when compared to normal.
Department of Pharmacology Page 57
Table.: Effect of ethanolic extract of Canthiumdicoccum on atherogenic index in 
triton x induced hyperlipidemicrats.
All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by multiple comparision of Dunnett’s test, **p<0.01 as compared to control.
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Treated Group Atherogenic 
Index
Sham operated Normal 0.31±0.01
Control (Triton X 100) 0.85±0.19
Standard (ATS 
10mg/kg)
0.31±0.09**
ECD 200mg/kg 0.91±0.24ns
ECD 400mg/kg 0.53±0.21ns
Fig.2: Effect of ethanolic extract of Canthiumdicoccum on serum cholesterol level in 
triton x induced hyperlipidemicrats.
Total Cholesterol
0
50
100
150
Normal
Control (Triton x 100)
STD (Atorvastatin 10mg/kg)
ECD (200mg/kg)
ECD (400mg/kg)
a
***
***
***
Groups
m
g/
dl
All  the  values  are  Mean±SEM,  n=6,  One  way  ANOVA  followed  by  multiple
comparision of Dunnett’s test,***p<0.001 as compared to control  and  ap<0.001 as
when compared to normal.
Fig.3: Effect of ethanolic extract of Canthiumdicoccum on serum triglyceride level
in triton x induced hyperlipidemicrats
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by  multiple  comparision  of  Dunnett’s  test,*p<0.05  as  compared  to  control  and
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bp<0.01 as when compared to normal.
Fig.4: Effect of ethanolic extract of Canthiumdicoccum on serum HDL cholesterol
level in triton x induced hyperlipidemicrats
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by  multiple  comparision  of  Dunnett’s  test,*p<0.05  as  compared  to  control  and
bp<0.01 as when compared to normal.
Fig.5: Effect of ethanolic extract of Canthiumdicoccum on serum LDL-cholesterol
level in triton x induced hyperlipidemicrats
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by multiple comparision of Dunnett’s test.
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Fig.6: Effect of ethanolic extract of Canthiumdicoccum on serum VLDL-
cholesterol level in triton x induced hyperlipidemicrats.
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by multiple comparision of  Dunnett’s  test,***p<0.001 as compared to  control  and
ap<0.001as when compared to normal.
Fig.7: Effect of ethanolic extract of Canthiumdicoccum on serum glucose level in 
triton x induced hyperlipidemicrats
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed
by multiple comparision of Dunnett’s test,*p<0.05,**p<0.01 as compared to control
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and ap<0.001 as when compared to normal.
Fig.8: Effect of ethanolic extract of Canthiumdicoccum on serum glucose level in 
triton x induced hyperlipidemicrats.
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All the values are Mean±SEM, n=6, ns= not significant, One way ANOVA followed 
by multiple comparision of Dunnett’s test **p<0.01 as compared to control group.
Histopathology of Liver Tissue
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Fig.9: Histopathology of Liver
(a) normal group showing normal architecture;  (b) Control (Triton x 100) showing
fatty  infiltration  and  granular  degeneration;  (c)  Standard  (Atorvastatin  10mg/kg)
treated  group  showing  negligible  cytoplasmic  fatty  infiltration  and  granular
degeneration;  (d)  ECD  200mg/kg  treated  group  showing  mild  to  moderate
cytoplasmic fatty infiltration and granular degeneration; (e) ECD 400mg/kg treated
group showing mild cytoplasmic fatty infiltration and mild granular degeneration.
I I- HIGH FAT DIED INDUCED HYPERLIPIDEMIA
1. Effect of ethanolic extract of Canthiumdicoccum on serum lipid profile, glucose
level and atherogenic index in HFD induced hyperlipidaemia in rats.
1. Effect on serum Total cholesterol level
Rats fed with HFD for  28 days  had increased serum TC level  (132.1±0.56) when
measured on 28 day. This was significantly higher (p<0.001) when compared to serum
TC levels in normal control rats (81.69±1.58).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had serum TC level of
(74.39±1.26)  when  measured  on  day 28th.  This  was  significantly  lower  (p<0.001)
when compared to serum TC levels in control (HFD) rats (132.1±0.56).
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HFD rats treated with extract 200 and 400mg/kg p.o.once daily had serum level of
(103.7±2.58and  87.37±2.82)  when  measured  on  day  28.  These  values  were
significantly lower (p<0.001 and p<0.001) when compared  to  serum TC levels  in
control (HFD) rats (132.1±0.56).
2. Effect on sermTriglycerides level
Rats fed with HFD for 28 days had increased serum TG (125.5±2.44) when measured
on 28 day. This was significantly higher (p<0.001) when compared to serum TG levels
in normal control rats (79.93±2.16).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had serum TG level of
(70.78±1.46) when measured on day 28. This was significantly lower (p<0.001) when
compared to serum TG levels in control (HFD) rats (125.5±2.44).
HFD rats treated with extract 200 and 400mg/kg p.o. once daily had serum TG level
of  (28.62±1.54and  27.63±2.29)  when  measured  on  day  28.  These  values  were
significantly lower (p<0.01 and p<0.01) when compared to serum TC levels in control
(HFD) rats (125.5±2.44).
3. Effect on serum HDL-C level
Rats fed with HFD had increased serum HDL level (20.61±1.00) when measured on
28 day. This was significantly lower (p<0.01) when compared to serum HDL levels in
normal control rats (28.49±1.23).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had serum HDL level of
(31.97±0.90) when measured on day 28. This was significantly higher (p<0.001) when
compared to serum HDL levels in control (HFD) rats (20.61±1.00).
HFD rats treated with extract 200 and 400mg/kg p.o. once daily had serum HDL level
of  (28.62±1.54and  27.63±2.29)  when  measured  on  day  28.  These  values  were
significantly higher  (p<0.01  and  p<0.01) when compared  to  serum HDL levels  in
control (HFD) rats (20.61±1.00).
4. Effect on serum LDL-C level
Rats fed with HFD had increased serum LDL level (64.71±1.60) when measured on
28 day. This was significantly lower (p<0.001) when compared to serum LDL levels
in normal control rats (40.35±1.00).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had serum LDL level of
(34.41±1.53) when measured on day 28. This was significantly lower (p<0.001) when
compared to serum LDL levels in control (HFD) rats (64.71±1.60).
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HFD rats treated with extract 200 and 400mg/kg p.o. once daily had serum LDL level
of  (54.67±1.33and  41.38±0.27)  when  measured  on  day  28.  These  values  were
significantly lower (p<0.001 and p<0.001) when compared to serum LDL levels in
control (HFD) rats (64.71±1.60).
5. Effect on serum VLDL-C level
Rats fed with HFD had increased serum VLDL level (24.99±1.13) when measured on
28 day. This was significantly lower (p<0.001) when compared to serum VLDL levels
in normal control rats (14.93±1.23).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had serum VLDL level
of (12.00±0.17) when measured on day 28. This was significantly lower (p<0.001)
when compared to serum VLDL levels in control (HFD) rats (24.99±1.13).
HFD rats treated with extract 200 and 400mg/kg p.o. once daily had serum VLDL
level of (19.80±0.57and 18.81±0.79) when measured on day 28. This was significantly
lower (p<0.05 and p<0.01) when compared to serum VLDL levels in control (HFD)
rats (24.99±1.13).
6. Effect on serum glucose level
Rats fed with HFD had increased serum glucose level (83.19±2.90) when measured on
28 day.  This  was significantly higher  (p<0.001) when compared to serum glucose
levels in normal control rats (54.24±3.95).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had serum glucose level
of (52.18±2.34) when measured on day 28. This was significantly lower (p<0.001)
when compared to serum glucose levels in control (HFD) rats (83.19±2.90).
HFD rats treated with extract 200 and 400mg/kg p.o. once daily had serum glucose
level of (73.71±3.84and 68.47±1.96) when measured on day 28. These values were
significantly lower (p<0.05 and p<0.01) when compared to serum glucose levels in
control (HFD) rats (83.19±2.90).
7. Effect on AI
Rats fed with HFD had increased atherogenic index (5.73±0.56) when measured on
28th day.  This  was significantly higher  (p<0.001) when compared to AI in  normal
control rats (1.61±0.08).
HFD rats treated with Atorvastatin (10mg/kg, p.o. once daily) had AI of (1.83±0.16)
when measured on day 28. This was significantly lower (p<0.001) when compared to
AI in control (HFD) rats (5.73±0.56).
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HFD  rats  treated  with  extract  200  and  400mg/kg  p.o.  once  daily  had  AI  of
(3.61±0.59and 2.75±0.29) when measured on day 8. These values weresignificantly
lower (p<0.01 and p<0.001) when compared to AI in control (HFD) rats (5.73±0.56).
Table.3: Effect of ethanolic extract of Canthiumdicoccum on serum lipid profile and 
All  the  values  are  Mean±SEM,  n=6,  One  way  ANOVA  followed  by  multiple
comparision of Dunnett’s test,*p<0.05,**p<0.01, ***p<0.001 as compared to control
and ap<0.001,bp<0.01 as when compared to normal.
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Treated 
groups Serum Lipid profile and Glucose mg/dl
TC mg/dl TG mg/dl HDL mg/dl LDL mg/dl VLDL mg/dl Glucose 
mg/dl
Sham 
operated 
Normal
81.69±1.58 79.93±2.16 28.49±1.23 40.35±1.00 14.93±1.23 54.24±3.95
Control 
(HFD)
132.1±0.56a 125.5±2.44a 20.61±1.00b 64.71±1.60a 24.99±1.13a 83.19±2.90a
Standard
(ATS 
10mg/kg)
74.39±1.26**
*
70.78±1.46**
*
31.97±0.90**
*
34.41±1.53**
*
14.37±1.57**
*
52.18±2.34**
*
ECD 
200mg/k
103.7±2.58**
*
105.8±3.35**
*
28.62±1.54** 54.67±1.33**
*
19.80±0.57* 73.71±3.84*
ECD 
400mg/k
87.37±2.82**
*
89.41±2.73**
*
27.63±2.29** 41.38±0.27**
*
18.81±0.79** 68.47±1.96**
Table.4: Effect of ethanolic extract of Canthiumdicoccum on atherogenic index in 
HFD induced hyperlipidemicrats.
 
Fig.10:  Effect  of  ethanolic  extract  of  Canthiumdicoccum on  serum cholesterol
level in HFD induced hyperlipidemicrats.
Total Cholesterol
0
50
100
150
Normal
Control (HFD)
STD (Atorvastatin 10mg/kg)
ECD (200mg/kg)
ECD (400mg/kg)
a
***
***
***
Groups
m
g/
dl
All the values are Mean±SEM, n=6, One way ANOVA followed by multiple 
comparision of Dunnett’s test,***p<0.001 as compared to control and ap<0.001as 
when compared to normal.
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Treated Gruop Atherogenic Index
1  Normal 1.61±0.08
2 Control (Triton X 100) 5.73±0.56a
3 Standard (ATS 10mg/kg) 1.83±0.16***
4 ECD 200mg/kg 3.61±0.59**
5 ECD 400mg/kg           2.75±0.29***
Fig.11: Effect of ethanolic extract of Canthiumdicoccum on serum triglyceride 
level in HFD induced hyperlipidemicrats.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple 
comparison of Dunnett’s test,***p<0.001 as compared to control and ap<0.001 as 
when compared to normal.
Fig.12: Effect of ethanolic extract of Canthiumdicoccum on serum HDL level in 
HFD induced hyperlipidemicrats.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple 
comparison of Dunnett’s test,**p<0.01, ***p<0.001 as compared to control and 
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bp<0.01 as when compared to normal.
Fig.13: Effect of ethanolic extract of Canthiumdicoccum on serum LDL level in 
HFD induced hyperlipidemicrats.
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All  the  values  are  Mean±SEM,  n=6,  One  way  ANOVA  followed  by  multiple
comparision of Dunnett’s test,***p<0.001 as compared to control  and  ap<0.001 as
when compared to normal.
Fig.14: Effect of ethanolic extract of Canthiumdicoccum on serum VLDL level in 
HFD induced hyperlipidemicrats.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple 
comparision of Dunnett’s test,*p<0.05,**p<0.01, ***p<0.001 as compared to control 
Department of Pharmacology Page 69
and ap<0.001 as when compared to normal.
Fig.15: Effect of ethanolic extract of Canthiumdicoccum on serum glucose level in
HFD induced hyperlipidemicrats.
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All  the  values  are  Mean±SEM,  n=6,  One  way  ANOVA  followed  by  multiple
comparision of Dunnett’s test,*p<0.05,**p<0.01, ***p<0.001 as compared to control
and ap<0.001 as when compared to normal.
Fig.16: Effect of ethanolic extract of Canthiumdicoccum on serum AI in HFD 
induced hyperlipidemicrats
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All  the  values  are  Mean±SEM,  n=6,  One  way  ANOVA  followed  by  multiple
comparision  of  Dunnett’s  test,**p<0.01,  ***p<0.001  as  compared  to  control  and
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ap<0.001 as when compared to normal.
Effect of ethanolic extract of Canthiumdicoccum on histopathological changes in 
aorta of rats fed with HFD for 28 days.
1. Normal Group: Light microscopy of the aortic sections of normal group showed
normal histology of the tunica intima, media and adventia. The intima was composed
of a continuous layer of endothelial cells.
2.  Control  Group:Light  microscopy of  the  aortic  sections  of  HFD control  group
showed thickening of vascular wall of aortic musculature with fatty tissue. Also there
is a formation of neointima containing vascular smooth muscles cells of tunica media.
3. Standard Group:Light microscopy of the aortic sections of HFD and Atorvastatin
10mg/kg showed thickening of vascular wall of aortic musculature with fatty tissue.
Moderately decreased the formation of neointima and vascular smooth muscle cells of
tunica media are less in the neointima.
. ECD 200mg/kg group:Light microscopy of the aortic sections of HFD and ethanolic
extract of canthiumdicoccum 200mg/kg treated group showed thickening of vascular
wall of aortic musculature with fatty tissue. Mild decrease of formation of neointima
containing vascular smooth muscle cells of tunica media.
 ECD 400mg/kg: Light  microscopy of  the  aortic  sections  of  HFD and  400mg/kg
treated group showed thickening of  vascular  wall  of  aortic  musculature with fatty
tissue. There is mild formation of neointima containing vascular smooth muscle cells
of tunica media and almost there is a appearance of normal architecture.
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Fig.17: Effect of ethanolic extract of Canthiumdicoccum on histopathological
changes in aorta of rats fed with HFD for 28 days.
Fig.18: Histopathology of Aorta
A: Normal group,       B: Control (HFD) group,     C: Standard (Atorvastatin 
10mg/kg),      D: ECD (200mg/kg),    E: ECD (400mg/kg)
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                                                           VII. DISCUSSION 
The dried and powdered whole plant material of Canthium dicoccumwas subjected to
soxhlet extraction with 90 % ethanol and yielded 10 % w/w. Phytochemical analysis of the plant
extract showed different phytoconstituents viz. glycosides, phytosterols, triterpinoids, alkaloids
and flavonoids. Several phytoconstituents like glycosides, triterpinoids, Saponins, alkaloids and
flavonoids are known to have antihyperlipidemic properties.
It has been well established that nutrition plays an important role in the etiology of
hyperlipidemia and atherosclerosis76.  In  our study we chosen Triton x-100 and high fat  died
model. Triton-x-100 model is used as a acute model for induction of hyperlipdemia in rats and
another model that is HFD which contain the common ingredient in our daily food.
Cholesterol feeding has been often used to elevate serum cholesterol levels to assess
the  hypercholesterolemia-related  metabolic  disturbances  in  animals77,78.  Cholesterol  feeding
alone however doesnot affect the serum TG level. It is assumed that a high level of saturated fat
in addition to cholesterol is required to significantly elevate serum TG level in rat model.79
Triton induced hyperlipidemia in rats is an acute model for the primary screening of
antihyperlipidemic agents. TR acts as a surfactant and supresses the action of lipases to block the
uptake of lipoproteins from circulation by extra hepatic tissues, thereby increasing blood lipid
levels.80 TR  induced  hyperlipidemia  occurs  in  2  phases.  Drugs  interfering  cholesterol
biosynthesis are active in I, while drugs interfering with cholesterol excretion and metabolism
are active in phase II, ECD treatment significantly decreased total lipids in phase I and phase II.
The hypolipidemic activity of ECD was evident in both synthesis and excretory phases of triton
induced hyperlipidemia in rats.
The drug ECD showed protective action by increasing HDL-C level.  The possible
mechanism of activity may be due to the activity of LCAT and inhibition of the action of TG-
lipase on HDL which may contribute for a rapid catabolism of blood lipids through extra hepatic
tissue81.
High level of portal free fatty acids has been associated with insulin resistance and
glucose intolerance.66 High levels of blood circulating triglycerides interfere with insulin action
due to its receptor.82 These findings demonstrated that the improvement of physiological action
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of insulin action and prevention of insulin resistance by increasing insulin receptor binding may
be the possible antihypeglycemic mechanism of ECD.83
Diet containing saturated fatty acids increases the activity of HMG CoA reductase, the
rate determining enzyme in cholesterol biosynthesis; this may be due to higher availability of
acetyl CoA, which stimulated the cholesterogenesis rate. Moreover, this could be associated with
a down regulation in LDL receptors by the cholesterol and saturated fatty acids in the diet, which
could  also  explain  the  elevation  of  serum LDL-C levels  either  by changing  hepatic  LDLR
(LDLreceptor) activity, the LDL-C production rate or both. LCAT enzyme is involved in the
transesterification of cholesterol, the maturation of HDL-C and the flux of cholesterol from cell
membranes  into  HDL.  The  activity  of  the  enzyme  tends  to  decrease  in  diet-induced
hypercholesterolemia. 
The possible mechanism of ECD may involve increase of HDL-C, which is attributed
to the mobilization of cholesterol from peripheral  cells to the liver by the action of Lecithin
Cholesterol O-acyltransferase (LCAT) .The increased HDL-C facilitates the transport of TG or
cholesterol from serum to liver by a pathway termed ‘reverse cholesterol transport’ where it is
catabolised and excreted out of the body.
Antihyperlipidemic activity was observed withAtorvastatin (10mg/kg p.o.,), and the
ECD (400mg/kg) showed better activity than ECD (200mg/kg).
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                         In conclusion the findings of the study suggest that ECD is a potent
antihypercholesterolemic,  antihyperglycerolemic  drug lowering LDL,  VLDL and  increasing
HDL levels in all the two models such as Triton x 100 and HFD. The mechanism has point
towards cholesterol and triglyceride synthesis.
                      The drugs has also seems have potent antihyperglycemic activity which has been
seen  in  all  the  two  models.  The  mechanism  for  antihyperglycemic  activity  may  be  by
improving insulin sensitivity and by decreasing TG level.
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 The  present  was  carried  out  evaluate  antihyperlipidemic  activity  of  Canthiumdicoccum
commonly known asPlectronia didymium.This plant has been claimed to cure anthelmintic,
galactogogue, disorder of throat. Review of literature reveals that canthiumdicoccum has
shown the analgesic, antipyretic, diarrhea, rheumatic pains, anti-inflammatory, antifungal,
bone fractures, and bark is used as febrifuge and also applied as plasters.
 Evaluation of antihyperlipidemic activity was assessed by using two experimental models
namely acute and chronic hyperlidemic models.
 Acute hyperlipidemia was induced by administration of TR -x-100 (100mg/kg i.p, at once)
in male rats.
 Chronic hyperlipidemia was induced by feeding male rats high fat diet for 28 days.
 Administration  of  ECD  (200/400mg/kg.p.o)for  7/28  days  in  TR  and  HFD  models
respectively, successfully prevented the elevation of serum glucose levels.
 Treatment with ECD (200 and 400mg/kg) for 7/28 days successfully prevented the elevated
serum TG, TC, LDL-c and decrease of serum HDL-c in TR model rats.
 Administration  of  ECD  (200  and  400mg/kg)  for  7/28  days  successfully  prevented  the
elevated serum TG, TC, LDL-c and decrease of serum HDL-c in HFD model rats.
 Extract showed significant results of histopathology in liver and aorta tissues.
 The antihyperlipidemic activity was due to its phytochemical constituents like alkaloidal
and presence of glycoside. More investigation is necessary to prove the antihyperlipidemic
activity of Canthium dicoccum by other experimental models.
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